uniQure Stock Plunged 49% After FDA Rift—Class Action Deadline Looms for Investors

uniQure ($QURE) shareholders who suffered substantial losses during a critical period this fall now have a legal pathway to recoup damages through a class action lawsuit being investigated by prominent securities firm Hagens Berman. The biotechnology company's stock suffered a devastating 49% single-day collapse on November 3, 2025, when the market learned that the company had fundamentally misrepresented its interactions with the FDA regarding its experimental gene therapy candidate AMT-130. Investors who experienced losses between September 24 and October 31, 2025—the period when uniQure's misleading statements were in circulation—have until April 13, 2026 to join the litigation.

The FDA Controversy and Alleged Misrepresentations

At the heart of the investigation lies a serious allegation: uniQure allegedly misrepresented the nature and substance of its interactions with FDA officials regarding the regulatory pathway for AMT-130, a gene therapy candidate in development. According to Hagens Berman's investigation, the company made problematic claims about FDA feedback that did not align with what regulators actually communicated.

The specific issues cited include:

• Distorted comparisons: FDA officials publicly criticized uniQure for distorting comparisons in how it presented AMT-130 data and efficacy claims
• Sham surgery downplaying: The company allegedly downplayed or mischaracterized the role of sham surgery requirements that FDA had mandated for the study design
• Unapproved study design: uniQure used an unapproved study design for AMT-130 without properly disclosing the regulatory disagreement to investors

These misrepresentations appear to have been material to investor decision-making. The dramatic stock price collapse suggests the market had been pricing uniQure based on an overly optimistic regulatory narrative that did not reflect actual FDA sentiment.

Market Context: Gene Therapy Under Regulatory Scrutiny

The uniQure situation unfolds within a challenging environment for gene therapy developers. The sector has faced increasing regulatory skepticism, with the FDA adopting more rigorous standards for early-stage therapies, particularly around study design and the interpretation of clinical efficacy data.

Gene therapy companies have come under particular pressure to demonstrate not just biological activity but clear clinical benefit in controlled trial settings. The use of sham surgeries in gene therapy trials—while standard practice in some therapeutic areas—has become a point of contention between developers and regulators, with the FDA increasingly insistent on rigorous controls.

uniQure's experience mirrors broader challenges in the biotech sector:

• Regulatory stringency: Gene therapy candidates face heightened FDA scrutiny compared to small-molecule drugs
• Trial design complexity: Companies must navigate increasingly demanding requirements for control arms and study methodology
• Communication risk: The gap between company optimism and regulatory reality has become a material risk factor for investors

The company's alleged misrepresentation of FDA feedback suggests a breakdown in transparency that may have inflated investor expectations about the likelihood of AMT-130 approval.

Investor Implications: A Critical Window for Legal Action

For shareholders who purchased $QURE stock during the period of alleged misrepresentation, the class action lawsuit represents a potential avenue for recovery. The November 3 crash revealed the extent to which the company's previous communications had diverged from regulatory reality—a gap that likely resulted in significant losses for shareholders.

Key timeline considerations for investors:

• Period of alleged misrepresentation: September 24 – October 31, 2025
• Stock price collapse: 49% decline on November 3, 2025 (disclosure date)
• Class action deadline: April 13, 2026
• Statute of limitations risk: Investors must file before the deadline or lose the right to participate

The magnitude of the single-day decline suggests the market had materially repriced uniQure once the true nature of FDA disagreements became public. This represents a classic case of alleged securities fraud where company statements materially misrepresented regulatory relationships that were central to the investment thesis.

Beyond uniQure specifically, this case carries implications for other gene therapy and biotech companies. It underscores the regulatory and disclosure risks inherent in biotechnology investing, particularly when companies make forward-looking claims about FDA interactions that could prove inaccurate. Investors in early-stage biotech firms should heighten scrutiny of how companies characterize regulatory feedback and study design discussions.

What's Next for uniQure and Investors

With the April 13, 2026 deadline approaching, shareholders with documented losses during the September-October 2025 window should carefully review their transaction records and consider consulting with securities counsel. The strength of any eventual settlement or judgment will depend on the degree to which uniQure's statements can be proven to have been knowingly or recklessly misleading.

Meanwhile, uniQure faces the more fundamental challenge of salvaging the AMT-130 program or redirecting its development strategy in alignment with actual FDA requirements. The company's ability to recover credibility with investors, regulators, and the broader market will likely depend on demonstrating transparency going forward and achieving meaningful clinical progress under FDA-approved study designs.

For the broader biotech investment community, the uniQure situation serves as a cautionary tale about the importance of independent verification of regulatory claims and the material risks posed by mischaracterizations of FDA feedback. As gene therapy continues to advance, maintaining clear and accurate communication with both regulators and investors will be essential for companies seeking to build sustainable shareholder value.